Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media.
View Top Employees from Theravance Biopharma US, Inc.Website | http://www.theravance.com/home |
Ticker | TBPH |
Revenue | $54.3 million |
Funding | $1.3 billion |
Employees | 259 (259 on RocketReach) |
Founded | 2014 |
Address | 901 Gateway Blvd., South San Francisco, California 94080, US |
Phone | (650) 808-6000 |
Industry | Biotechnology, Pharmaceuticals, Healthcare |
Web Rank | 4 Million |
Keywords | Copd Treatment, Respiratory Conditions, Specialty Medicine, Innovative Medicine, Respiratory Health, Drug Development And Manufacturing, Biopharmaceuticals |
Competitors | Akebia Therapeutics, Cytokinetics, Ironwood Pharmaceuticals, Omeros Corporation, Vanda Pharmaceuticals |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Theravance Biopharma US, Inc. employee's phone or email?
The Theravance Biopharma US, Inc. annual revenue was $54.3 million in 2024.
Jesse Fecker is the Vice President, Head of Intellectual Property of Theravance Biopharma US, Inc..
259 people are employed at Theravance Biopharma US, Inc..
Theravance Biopharma US, Inc. is based in South San Francisco, California.
The NAICS codes for Theravance Biopharma US, Inc. are [32541, 3254, 32, 325].
The SIC codes for Theravance Biopharma US, Inc. are [283, 28].